Anti-Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps.
adolescent
anti‐obesity agents
child
obesity
obesity management
paediatric obesity
review
Journal
Clinical endocrinology
ISSN: 1365-2265
Titre abrégé: Clin Endocrinol (Oxf)
Pays: England
ID NLM: 0346653
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
revised:
20
07
2024
received:
17
04
2024
accepted:
21
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
Paediatric obesity is a global public health concern. While in most countries the incidence keeps rising, the need for effective and long-term management for children and adolescents living with this chronic, relapsing disease is pressing. Health behaviour and lifestyle treatment (HBLT) is recommended as first-line treatment. Narrative review. A new generation of recently approved anti-obesity medications (AOM) now has the potential to fill the gap between limited effects on body mass index (BMI) by HBLT alone and large effects by metabolic and bariatric surgery in adolescents with obesity aged 12 years and older. While, for semaglutide and phentermine/topiramate, effectiveness is substantial with relevant, but mostly mild to moderate adverse events, there is a gap in evidence regarding long-term effects and safety, effects on outcomes beyond BMI reduction and data for certain groups of patients, such as children < 12 years and minority groups. When integrating AOM treatment into national healthcare systems it should be offered as part of a comprehensive patient-centred approach. This article summarizes recent AOM developments, integration into paediatric obesity management, and identifies research gaps.
Sections du résumé
BACKGROUND
BACKGROUND
Paediatric obesity is a global public health concern. While in most countries the incidence keeps rising, the need for effective and long-term management for children and adolescents living with this chronic, relapsing disease is pressing. Health behaviour and lifestyle treatment (HBLT) is recommended as first-line treatment.
METHODS
METHODS
Narrative review.
RESULTS
RESULTS
A new generation of recently approved anti-obesity medications (AOM) now has the potential to fill the gap between limited effects on body mass index (BMI) by HBLT alone and large effects by metabolic and bariatric surgery in adolescents with obesity aged 12 years and older. While, for semaglutide and phentermine/topiramate, effectiveness is substantial with relevant, but mostly mild to moderate adverse events, there is a gap in evidence regarding long-term effects and safety, effects on outcomes beyond BMI reduction and data for certain groups of patients, such as children < 12 years and minority groups. When integrating AOM treatment into national healthcare systems it should be offered as part of a comprehensive patient-centred approach.
CONCLUSION
CONCLUSIONS
This article summarizes recent AOM developments, integration into paediatric obesity management, and identifies research gaps.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Clinical Endocrinology published by John Wiley & Sons Ltd.
Références
T. Burki, “European Commission Classifies Obesity as a Chronic Disease,” Lancet Diabetes & Endocrinology 9, no. 7 (2021): 418, https://doi.org/10.1016/S2213-8587(21)00145-5.
N. H. Phelps, R. K. Singleton, and B. Zhou, et al., “Worldwide Trends in Underweight and Obesity From 1990 to 2022: A Pooled Analysis of 3663 Population‐Representative Studies With 222 Million Children, Adolescents, and Adults,” Lancet 403, no. 10431 (March 2024): 1027–1050, https://doi.org/10.1016/s0140-6736(23)02750-2.
N. B. Lister, L. A. Baur, J. F. Felix, et al., “Child and Adolescent Obesity,” Nature Reviews Disease Primers 9, no. 1 (May 2023): 24, https://doi.org/10.1038/s41572-023-00435-4.
D. S. Freedman, Z. Mei, S. R. Srinivasan, G. S. Berenson, and W. H. Dietz, “Cardiovascular Risk Factors and Excess Adiposity Among Overweight Children and Adolescents: The Bogalusa Heart Study,” Journal of Pediatrics 150, no. 1 (January 2007): 12–17.e2, https://doi.org/10.1016/j.jpeds.2006.08.042.
O. T. Raitakari, M. Juonala, M. Kähönen, et al., “Cardiovascular Risk Factors in Childhood and Carotid Artery Intima‐Media Thickness in Adulthood: The Cardiovascular Risk in Young Finns Study,” JAMA 290, no. 17 (November 2003): 2277–2283, https://doi.org/10.1001/jama.290.17.2277.
X. Fang, J. Zuo, J. Zhou, et al., “Childhood Obesity Leads to Adult Type 2 Diabetes and Coronary Artery Diseases: A 2‐sample Mendelian Randomization Study,” Medicine 98, no. 32 (August 2019): e16825, https://doi.org/10.1097/md.0000000000016825.
A. Llewellyn, M. Simmonds, C. G. Owen, and N. Woolacott, “Childhood Obesity as a Predictor of Morbidity in Adulthood: A Systematic Review and Meta‐Analysis,” Obesity Reviews 17, no. 1 (January 2016): 56–67, https://doi.org/10.1111/obr.12316.
S. Weihrauch‐Blüher, P. Schwarz, and J. H. Klusmann, “Childhood Obesity: Increased Risk for Cardiometabolic Disease and Cancer in Adulthood,” Metabolism 92 (March 2019): 147–152, https://doi.org/10.1016/j.metabol.2018.12.001.
H. Jebeile, A. S. Kelly, G. O'Malley, and L. A. Baur, “Obesity in Children and Adolescents: Epidemiology, Causes, Assessment, and Management,” Lancet Diabetes & Endocrinology 10, no. 5 (May 2022): 351–365, https://doi.org/10.1016/s2213-8587(22)00047-x.
A. Tirosh, I. Shai, A. Afek, et al., “Adolescent BMI Trajectory and Risk of Diabetes Versus Coronary Disease,” New England Journal of Medicine 364, no. 14 (April 2011): 1315–1325, https://doi.org/10.1056/NEJMoa1006992.
S. E. Hampl, S. G. Hassink, A. C. Skinner, et al., “Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity,” Pediatrics 151, no. 2 (2023): e2022060640, https://doi.org/10.1542/peds.2022-060640.
P. L. Valenzuela, P. Carrera‐Bastos, A. Castillo‐García, D. E. Lieberman, A. Santos‐Lozano, and A. Lucia, “Obesity and the Risk of Cardiometabolic Diseases,” Nature Reviews Cardiology 20, no. 7 (July 2023): 475–494, https://doi.org/10.1038/s41569-023-00847-5.
C. Bouchard, “Genetics of Obesity: What We Have Learned Over Decades of Research,” Obesity 29, no. 5 (May 2021): 802–820, https://doi.org/10.1002/oby.23116.
A. Hinney, A. Körner, and P. Fischer‐Posovszky, “The Promise of New Anti‐Obesity Therapies Arising From Knowledge of Genetic Obesity Traits,” Nature Reviews Endocrinology 18, no. 10 (October 2022): 623–637, https://doi.org/10.1038/s41574-022-00716-0.
A. S. Kelly, “Current and Future Pharmacotherapies for Obesity in Children and Adolescents,” Nature Reviews Endocrinology 19, no. 9 (September 2023): 534–541, https://doi.org/10.1038/s41574-023-00858-9.
D. J. Drucker, “GLP‐1 Physiology Informs the Pharmacotherapy of Obesity,” Molecular Metabolism 57 (March 2022): 101351, https://doi.org/10.1016/j.molmet.2021.101351.
P. Sumithran, L. A. Prendergast, E. Delbridge, et al., “Long‐Term Persistence of Hormonal Adaptations to Weight Loss,” New England Journal of Medicine 365, no. 17 (October 2011): 1597–1604, https://doi.org/10.1056/NEJMoa1105816.
J. P. H. Wilding, R. L. Batterham, M. Davies, et al., “Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The Step 1 Trial Extension,” Diabetes, Obesity and Metabolism 24, no. 8 (August 2022): 1553–1564, https://doi.org/10.1111/dom.14725.
S. F. Noria, R. D. Shelby, K. D. Atkins, N. T. Nguyen, and K. M. Gadde, “Weight Regain after Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment,” Current Diabetes Reports 23, no. 3 (March 2023): 31–42, https://doi.org/10.1007/s11892-023-01498-z.
H. Hanssen, T. Moholdt, M. Bahls, et al., “Lifestyle Interventions to Change Trajectories of Obesity‐Related Cardiovascular Risk From Childhood Onset to Manifestation in Adulthood: A Joint Scientific Statement of the Task Force for Childhood Health of the European Association of Preventive Cardiology and the European Childhood Obesity Group,” European Journal of Preventive Cardiology 30, no. 14 (October 10, 2023): 1462–1472, https://doi.org/10.1093/eurjpc/zwad152.
L. J. Ells, K. Rees, T. Brown, et al., “Interventions for Treating Children and Adolescents With Overweight and Obesity: An Overview of Cochrane Reviews,” International Journal of Obesity 42, no. 11 (November 2018): 1823–1833, https://doi.org/10.1038/s41366-018-0230-y.
Z. Wu, Z. Gao, Y. Qiao, et al., “Long‐Term Results of Bariatric Surgery in Adolescents With at Least 5 Years of Follow‐Up: A Systematic Review and Meta‐Analysis,” Obesity Surgery 33, no. 6 (June 2023): 1730–1745, https://doi.org/10.1007/s11695-023-06593-4.
G. Torbahn, J. Brauchmann, E. Axon, et al., “Surgery for the Treatment of Obesity in Children and Adolescents,” Cochrane Database of Systematic Reviews 2022, no. 9 (September 2022): Cd011740, https://doi.org/10.1002/14651858.CD011740.pub2.
K. Järvholm, A. Janson, M. Peltonen, et al., “Metabolic and Bariatric Surgery Versus Intensive Non‐Surgical Treatment for Adolescents With Severe Obesity (AMOS2): a Multicentre, Randomised, Controlled Trial in Sweden,” Lancet Child & Adolescent Health 7, no. 4 (April 2023): 249–260, https://doi.org/10.1016/s2352-4642(22)00373-x.
A. T. Mitra, B. Das, K. M. Sarraf, M. Ford‐Adams, M. Fehervari, and H. Ashrafian, “Bone Health Following Paediatric and Adolescent Bariatric Surgery: A Systematic Review and Meta‐Analysis,” EClinicalMedicine 69 (March 2024): 102462, https://doi.org/10.1016/j.eclinm.2024.102462.
B. S. Lennerz, M. Wabitsch, H. Lippert, et al., “Bariatric Surgery in Adolescents and Young Adults—Safety and Effectiveness in a Cohort of 345 Patients,” International Journal of Obesity 38, no. 3 (March 2014): 334–340, https://doi.org/10.1038/ijo.2013.182.
“Saxenda,” EMA, accessed October 10, 2023, https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda.
“ Wegovy,” EMA, accessed 10 June 2023, https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy.
“FDA Approves Treatment for Chronic Weight Management in Pediatric Patients Aged 12 Years and Older,” Food and Drug Administration, 2022, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-chronic-weight-management-pediatric-patients-aged-12-years-and-older.
M. Vallis, E. Boyland, M. Caroli, et al., “Adherence to Treatment Recommendations in Chronic Disease: What Is (Im)Possible? Expert Conclusions From the 30th ECOG Workshop 2021,” Annals of Nutrition and Metabolism 78, no. 6 (2022): 352–358, https://doi.org/10.1159/000526406.
R. E. Glasgow, C. Tracy Orleans, E. H. Wagner, S. J. Curry, and L. I. Solberg, “Does the Chronic Care Model Serve Also as a Template for Improving Prevention?” The Milbank Quarterly 79, no. 4 (2001): 579–612. iv‐v, https://doi.org/10.1111/1468-0009.00222.
K. B. Suire, J. Kavookjian, and D. D. Wadsworth, “Motivational Interviewing for Overweight Children: A Systematic Review,” Pediatrics 146, no. 5 (November 2020): e20200193, https://doi.org/10.1542/peds.2020-0193.
M. Vallis, D. Lee‐Baggley, T. Sampalli, et al., “Equipping Providers With Principles, Knowledge and Skills to Successfully Integrate Behaviour Change Counselling Into Practice: A Primary Healthcare Framework,” Public Health 154 (January 2018): 70–78, https://doi.org/10.1016/j.puhe.2017.10.022.
J. A. Welsh, S. J. Lange, J. Figueroa, S. Walsh, H. Gooding, and P. Cheung, “Impact of a Brief Training on Motivational Interviewing and the 5A's Approach on Weight‐Related Counseling Practices of Pediatricians,” Obesity Science & Practice 8, no. 4 (August 2022): 466–473, https://doi.org/10.1002/osp4.588.
A. M. Osunlana, J. Asselin, R. Anderson, et al., “5As Team Obesity Intervention in Primary Care: Development and Evaluation of Shared Decision‐Making Weight Management Tools,” Clinical Obesity 5, no. 4 (August 2015): 219–225, https://doi.org/10.1111/cob.12105.
C. K. Fox, A. S. Kelly, J. L. Reilly, N. Theis‐Mahon, and S. J. Raatz, “Current and Future State of Pharmacological Management of Pediatric Obesity,” International Journal of Obesity. Published ahead of print, February 6, 2024, https://doi.org/10.1038/s41366-024-01465-y.
K. Clément, E. den Akker, van, and J. Argente, et al., “Efficacy and Safety of Setmelanotide, an Mc4r Agonist, in Individuals With Severe Obesity Due to Lepr or Pomc Deficiency: Single‐Arm, Open‐Label, Multicentre, Phase 3 Trials,” Lancet Diabetes & endocrinology 8, no. 12 (December 2020): 960–970, https://doi.org/10.1016/s2213-8587(20)30364-8.
A. M. Haqq, W. K. Chung, H. Dollfus, et al., “Efficacy and Safety of Setmelanotide, a Melanocortin‐4 Receptor Agonist, in Patients With Bardet‐Biedl Syndrome and Alström Syndrome: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled, Phase 3 Trial With an Open‐Label Period,” Lancet Diabetes & Endocrinology 10, no. 12 (December 2022): 859–868, https://doi.org/10.1016/s2213-8587(22)00277-7.
“Approves Treatment for Weight Management in Patients With Bardet‐Biedl Syndrome Aged 6 or Older, “Food and Drug Administration,” 2022, https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-weight-management-patients-bardet-biedl-syndrome-aged-6-or-older.
“Imcivree EPAR Product Information,” European Medicines Agency, 2023, https://www.ema.europa.eu/en/documents/product-information/imcivree-epar-product-information_de.pdf.
“New Treatment for Obesity Caused by Rare Genetic Disorders,” European Medicines Agency, 2021, https://www.ema.europa.eu/en/news/new-treatment-obesity-caused-rare-genetic-disorders.
“Myalepta,” European Medicine Agency, accessed July 20, 2024, https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta.
Evidence Review: Metreleptin for Congenital Leptin Deficiency (All Ages)“NHS England,” 2018, https://www.england.nhs.uk/wp-content/uploads/2018/12/Evidence-review-Metreleptin-for-congenital-leptin-deficiency.pdf.
M. Wabitsch, J. B. Funcke, B. Lennerz, et al., “Biologically Inactive Leptin and Early‐Onset Extreme Obesity,” New England Journal of Medicine 372, no. 1 (January 2015): 48–54, https://doi.org/10.1056/NEJMoa1406653.
J. B. Funcke, B. Moepps, J. Roos, et al., “Rare Antagonistic Leptin Variants and Severe, Early‐Onset Obesity,” New England Journal of Medicine 388, no. 24 (June 15, 2023): 2253–2261, https://doi.org/10.1056/NEJMoa2204041.
J. von Schnurbein, S. Zorn, A. Nunziata, et al., “Classification of Congenital Leptin Deficiency,” Journal of Clinical Endocrinology and Metabolism (2024), https://doi.org/10.1210/clinem/dgae149.
G. Paz‐Filho, M. L. Wong, and J. Licinio, “Ten Years of Leptin Replacement Therapy,” Obesity Reviews 12, no. 5 (May 2011): e315–e323, https://doi.org/10.1111/j.1467-789X.2010.00840.x.
M. W. Haymond, D. Araújo‐Vilar, J. Balser, et al., “The Metreleptin Effectiveness and Safety Registry (Measure): Concept, Design and Challenges,” Orphanet Journal of Rare Diseases 18, no. 1 (May 2023): 127, https://doi.org/10.1186/s13023-023-02714-5.
E. Axon, G. Atkinson, B. Richter, et al., “Drug Interventions for the Treatment of Obesity in Children and Adolescents,” Cochrane Database of Systematic Reviews 2020, no. 11 (November 2016): Cd012436, https://doi.org/10.1002/14651858.Cd012436.
Q. Shi, Y. Wang, Q. Hao, et al., “Pharmacotherapy for Adults With Overweight and Obesity: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials,” Lancet 399, no. 10321 (January 2022): 259–269, https://doi.org/10.1016/s0140-6736(21)01640-8.
G. Torbahn, A. Jones, A. Griffiths, et al., “Pharmacological Interventions for the Management of Children and Adolescents Living With Obesity—An Update of a Cochrane Systematic Review With Meta‐Analyses,” Pediatric Obesity 19, no. 5 (May 2024): e13113, https://doi.org/10.1111/ijpo.13113.
D. Weghuber, T. Barrett, M. Barrientos‐Pérez, et al., “Once‐Weekly Semaglutide in Adolescents With Obesity,” New England Journal of Medicine 387 (November 2022): 2245–2257, https://doi.org/10.1056/NEJMoa2208601.
A. S. Kelly, S. Arslanian, D. Hesse, et al., “Reducing BMI below the Obesity Threshold in Adolescents Treated With Once‐Weekly Subcutaneous Semaglutide 2.4 Mg,” Obesity 31, no. 8 (August 2023): 2139–2149, https://doi.org/10.1002/oby.23808.
M. Sodhi, R. Rezaeianzadeh, A. Kezouh, and M. Etminan, “Risk of Gastrointestinal Adverse Events Associated With Glucagon‐Like Peptide‐1 Receptor Agonists for Weight Loss,” JAMA 330, no. 18 (November 2023): 1795–1797, https://doi.org/10.1001/jama.2023.19574.
T. Makunts, H. Joulfayan, and R. Abagyan, “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon‐Like Peptide‐1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis,” JMIRx Med 5 (May 1, 2024): e55976, https://doi.org/10.2196/55976.
D. J. Drucker, “Efficacy and Safety of Glp‐1 Medicines for Type 2 Diabetes and Obesity,” Diabetes Care. Published ahead of print, June 6, 2024, https://doi.org/10.2337/dci24-0003.
G. Torbahn, A. Jones, A. Griffiths, et al., “Pharmacological Interventions for the Management of Children and Adolescents Living With Obesity—An Update of a Cochrane Systematic Review With Meta‐Analyses,” Pediatric Obesity 19 (2024): e13113, https://doi.org/10.1111/ijpo.13113.
P. Kühnen, H. Biebermann, and S. Wiegand, “Pharmacotherapy in Childhood Obesity,” Hormone Research in Paediatrics 95, no. 2 (2022): 177–192, https://doi.org/10.1159/000518432.
A. Floegel‐Shetty, “Should Pharmaceuticals Be Used as Weight Loss Interventions for Adolescents Classified as Obese by BMI?,” AMA Journal of Ethics 25, no. 7 (July 2023): E478–E495, https://doi.org/10.1001/amajethics.2023.478.
V. Guglielmi, S. Bettini, P. Sbraccia, et al., “Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti‐Obesity Medications,” Current Obesity Reports 12, no. 2 (June 2023): 127–146, https://doi.org/10.1007/s13679-023-00502-7.
E. A. O'Connor, C. V. Evans, B. U. Burda, E. S. Walsh, M. Eder, and P. Lozano, “Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the Us Preventive Services Task Force,” JAMA 317, no. 23 (June 2017): 2427–2444, https://doi.org/10.1001/jama.2017.0332.
E. A. O'Connor, C. V. Evans, B. U. Burda, E. S. Walsh, M. Eder and P. Lozano, Screening for Obesity and Interventions for Weight Management in Children and Adolescents: A Systematic Evidence Review for the U.S. Preventive Services Task Force (Rockville, MD: Agency for Healthcare Research and Quality [US], 2017), https://www.ncbi.nlm.nih.gov/books/NBK476325/.
S. Wiegand, K. M. Keller, T. Lob‐Corzilius, et al., “Predicting Weight Loss and Maintenance in Overweight/Obese Pediatric Patients,” Hormone Research in Paediatrics 82, no. 6 (2014): 380–387, https://doi.org/10.1159/000368963.
A. S. Kelly, M. O. Bensignor, D. S. Hsia, et al., “Phentermine/Topiramate for the Treatment of Adolescent Obesity,” NEJM Evidence 1, no. 6 (2022): EVIDoa2200014, https://doi.org/10.1056/EVIDoa2200014.
D. Weghuber, T. Barrett, M. Barrientos‐Pérez, et al., “Once‐Weekly Semaglutide in Adolescents With Obesity,” New England Journal of Medicine 387, no. 24 (December 2022): 2245–2257, https://doi.org/10.1056/NEJMoa2208601.
J. R. Ryder, A. M. Kaizer, T. M. Jenkins, A. S. Kelly, T. H. Inge, and G. Q. Shaibi, “Heterogeneity in Response to Treatment of Adolescents With Severe Obesity: The Need for Precision Obesity Medicine,” Obesity 27, no. 2 (February 2019): 288–294, https://doi.org/10.1002/oby.22369.
L. Amaro‐Álvarez, J. Cordero‐Ramos, and M. Á. Calleja‐Hernández, “Exploring the Impact of Pharmacogenetics on Personalized Medicine: A Systematic Review,” Farmacia Hospitalaria. Published ahead of print, February 9, 2024, https://doi.org/10.1016/j.farma.2023.12.004.
J. C. G. Halford, A. Bereket, B. Bin‐Abbas, et al., “Misalignment Among Adolescents Living With Obesity, Caregivers, and Healthcare Professionals: Action Teens Global Survey Study,” Pediatric Obesity 17, no. 11 (November 2022): e12957, https://doi.org/10.1111/ijpo.12957.
I. S. Zenlea, M. Sebastianski, M. Kucera, et al., “Incorporation of Patient and Family Values and Preferences for Health‐Related Outcomes in Paediatric Obesity Management: A Systematic Review,” Pediatric Obesity 18, no. 5 (May 2023): e13006, https://doi.org/10.1111/ijpo.13006.
“Multistakeholder Workshop on Shortages of Glucagon‐Like Peptide‐1 (GLP‐1) Receptor Agonists,” European Medicines Agency, 2024, https://www.ema.europa.eu/en/events/multistakeholder-workshop-shortages-glucagon-peptide-1-glp-1-receptor-agonists#:~:text=A%20shortage%20of%20medicines%20containing,such%20as%20manufacturing%20capacity%20constraints.
A. S. Kelly, P. Auerbach, M. Barrientos‐Perez, et al., “A Randomized, Controlled Trial of Liraglutide for Adolescents With Obesity,” New England Journal of Medicine 382, no. 22 (May 2020): 2117–2128, https://doi.org/10.1056/NEJMoa1916038.
L. J. Aronne, N. Sattar, D. B. Horn, et al., “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The Surmount‐4 Randomized Clinical Trial,” JAMA 331, no. 1 (January 2024): 38–48, https://doi.org/10.1001/jama.2023.24945.
M. A. Baak, van, and E. C. M. Mariman, “Obesity‐Induced and Weight‐Loss‐Induced Physiological Factors Affecting Weight Regain,” Nature Reviews Endocrinology 19, no. 11 (November 2023): 655–670, https://doi.org/10.1038/s41574-023-00887-4.
S. B. K. Jensen, C. Janus, J. R. Lundgren, et al., “Exploratory Analysis of Eating‐ and Physical Activity‐Related Outcomes From a Randomized Controlled Trial for Weight Loss Maintenance With Exercise and Liraglutide Single or Combination Treatment,” Nature Communications 13, no. 1 (August 2022): 4770, https://doi.org/10.1038/s41467-022-32307-y.
M. Aldawsari, F. A. Almadani, N. Almuhammadi, S. Algabsani, Y. Alamro, and M. Aldhwayan, “The Efficacy of GLP‐1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults With Obesity: Systematic Review of Randomized Controlled Trials,” Diabetes, Metabolic Syndrome and Obesity 16 (2023): 575–595, https://doi.org/10.2147/dmso.S387116.
“Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56‐Week, Double‐Blind, Randomised, Placebo‐Controlled Trial,” National Library of Medicine, accessed September 4, 2024, https://clinicaltrials.gov/study/NCT04775082.
“Long‐term Safety and Efficacy of Semaglutide s.c. Once‐Weekly on Weight Management in Children and Adolescents (Aged 6 to <18 Years) With Obesity or Overweight,” National Library of Medicine, accessed September 4, 2024, https://clinicaltrials.gov/study/NCT05726227.
“Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight‐Related Comorbidities: A Randomized, Double‐Blind Trial (SURMOUNT‐ADOLESCENTS),” National Library of Medicine, accessed September 4, 2024, https://clinicaltrials.gov/study/NCT06075667.
“A Safety Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity,” National Library of Medicine, accessed September 4, 2024, https://clinicaltrials.gov/study/NCT05696847.
O. S. Alkhezi, A. A. Alahmed, O. M. Alfayez, O. A. Alzuman, A. R. Almutairi, and O. A. Almohammed, “Comparative Effectiveness of Glucagon‐Like Peptide‐1 Receptor Agonists for the Management of Obesity in Adults Without Diabetes: A Network Meta‐Analysis of Randomized Clinical Trials,” Obesity Reviews 24, no. 3 (March 2023): e13543, https://doi.org/10.1111/obr.13543.
A. M. Jastreboff, L. M. Kaplan, J. P. Frías, et al., “Triple‐Hormone‐Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial,” New England Journal of Medicine 389, no. 6 (August 2023): 514–526, https://doi.org/10.1056/NEJMoa2301972.
M. Chakhtoura, R. Haber, M. Ghezzawi, C. Rhayem, R. Tcheroyan, and C. S. Mantzoros, “Pharmacotherapy of Obesity: An Update on the Available Medications and Drugs Under Investigation,” EClinicalMedicine 58 (April 2023): 101882, https://doi.org/10.1016/j.eclinm.2023.101882.
F. C. Stanford, “A New Era in Obesity Management,” Nature Reviews Gastroenterology & Hepatology 21, no. 2 (February 2023): 80–81, https://doi.org/10.1038/s41575-023-00887-9.
K. C. Carlsson Petri, P. M. Hale, D. Hesse, N. Rathor, and L. D. Mastrandrea, “Liraglutide Pharmacokinetics and Exposure‐Response in Adolescents With Obesity,” Pediatric Obesity 16, no. 10 (October 2021): e12799, https://doi.org/10.1111/ijpo.12799.
P. Roser, S. S. Bajaj, and F. C. Stanford, “International Lack of Equity in Modern Obesity Therapy: The Critical Need for Change in Health Policy,” International Journal of Obesity 46, no. 9 (September 2022): 1571–1572, https://doi.org/10.1038/s41366-022-01176-2.
J. Levi, J. Wang, F. Venter, and A. Hill, “Estimated Minimum Prices and Lowest Available National Prices for Antiobesity Medications: Improving Affordability and Access to Treatment,” Obesity 31, no. 5 (May 2023): 1270–1279, https://doi.org/10.1002/oby.23725.
F. Lim, B. K. Bellows, S. X. Tan, et al., “Cost‐Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents,” JAMA Network Open 6, no. 8 (August 2023): e2329178, https://doi.org/10.1001/jamanetworkopen.2023.29178.
S. Mital and H. V. Nguyen, “Cost‐Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity,” JAMA Network Open 6, no. 10 (October 2023): e2336400, https://doi.org/10.1001/jamanetworkopen.2023.36400.
J. R. Richards and S. S. Khalsa, “Highway to the Danger Zone? A Cautionary Account That GLP‐1 Receptor Agonists May Be Too Effective for Unmonitored Weight Loss,” Obesity Reviews 25 (February 6, 2024): e13709, https://doi.org/10.1111/obr.13709.
D. M. Cooper, M. A. Rothstein, A. Amin, J. D. Hirsch, and E. Cooper, “Unintended Consequences of Glucagon‐Like peptide‐1 Receptor Agonists Medications in Children and Adolescents: A Call to Action,” Journal of Clinical and Translational Science 7, no. 1 (2023): e184, https://doi.org/10.1017/cts.2023.612.
R. Chivate, P. Schoemer, M. I. Ragavan, et al., “Primary Care Perspectives on Prescribing Anti‐Obesity Medication for Adolescents,” Pediatric Obesity 19 (June 2024): e13146, https://doi.org/10.1111/ijpo.13146.
J. D. Nobles, S. W. Flint, J. Saunders, and P. J. Gately, Mapping the Health System Response to Childhood Obesity in the WHO European Region (Copenhagen, Denmark: World Health Organization Regional Office for Europe, 2019), 1–98, https://iris.who.int/bitstream/handle/10665/346468/WHO-EURO-2019-3656-43415-60957-eng.pdf?sequence=1.
G. Torbahn, J. Lischka, C. Joisten, and D. Weghuber, “Pädiatrische Versorgungstrukturen bei Adipositas 2023—Wo stehen wir?” Monatsschrift Kinderheilkunde 171, no. 9 (September 2023): 784–795, https://doi.org/10.1007/s00112-023-01804-9.
M. Ryan, T. Hoffmann, R. Hofmann, and E. van Sluijs, “Incomplete Reporting of Complex Interventions: A Call to Action for Journal Editors to Review Their Submission Guidelines,” Trials 24, no. 1 (March 2023): 176, https://doi.org/10.1186/s13063-023-07215-1.
T. C. Hoffmann, P. P. Glasziou, I. Boutron, et al., “Better Reporting of Interventions: Template for Intervention Description and Replication (Tidier) Checklist and Guide,” BMJ 348 (March 2014): g1687, https://doi.org/10.1136/bmj.g1687.
T. A. Wadden, A. M. Chao, M. Moore, et al., “The Role of Lifestyle Modification With Second‐Generation Anti‐Obesity Medications: Comparisons, Questions, and Clinical Opportunities,” Current Obesity Reports 12, no. 4 (December 2023): 453–473, https://doi.org/10.1007/s13679-023-00534-z.
J. P. Almandoz, T. A. Wadden, and C. Tewksbury, et al., “Nutritional Considerations With Antiobesity Medications,” Obesity 32, no. 9 (2024): 1613–1631, https://doi.org/10.1002/oby.24067.
S. Wharton, M. Davies, D. Dicker, et al., “Managing the Gastrointestinal Side Effects of Glp‐1 Receptor Agonists in Obesity: Recommendations for Clinical Practice,” Postgraduate Medicine 134, no. 1 (January 2022): 14–19, https://doi.org/10.1080/00325481.2021.2002616.
J. R. Lundgren, C. Janus, S. B. K. Jensen, et al., “Healthy Weight Loss Maintenance With Exercise, Liraglutide, or Both Combined,” New England Journal of Medicine 384, no. 18 (May 2021): 1719–1730, https://doi.org/10.1056/NEJMoa2028198.
S. B. K. Jensen, M. B. Blond, R. M. Sandsdal, et al., “Healthy Weight Loss Maintenance With Exercise, GLP‐1 Receptor Agonist, or Both Combined Followed by One Year Without Treatment: A Post‐Treatment Analysis of a Randomised Placebo‐Controlled Trial,” EClinicalMedicine 69 (March 2024): 102475, https://doi.org/10.1016/j.eclinm.2024.102475.
J. M. Jakicic, R. J. Rogers, and T. S. Church, “Physical Activity in the New Era of Antiobesity Medications,” Obesity 32, no. 2 (February 2024): 234–236, https://doi.org/10.1002/oby.23930.
C. K. Fox, A. M. Kaizer, K. D. Rudser, et al., “Meal Replacements Followed by Topiramate for the Treatment of Adolescent Severe Obesity: A Pilot Randomized Controlled Trial,” Obesity 24, no. 12 (December 2016): 2553–2561, https://doi.org/10.1002/oby.21633.
C. K. Fox, J. M. Clark, K. D. Rudser, et al., “Exenatide for Weight‐Loss Maintenance in Adolescents With Severe Obesity: A Randomized, Placebo‐Controlled Trial,” Obesity 30, no. 5 (May 2022): 1105–1115, https://doi.org/10.1002/oby.23395.
J. P. Shonkoff, W. T. Boyce, P. Levitt, F. D. Martinez, and B. McEwen, “Leveraging the Biology of Adversity and Resilience to Transform Pediatric Practice,” Pediatrics 147, no. 2 (2021): e20193845, https://doi.org/10.1542/peds.2019-3845.
E. Guerrero‐Hreins, A. P. Goldstone, R. M. Brown, and P. Sumithran, “The Therapeutic Potential of GLP‐1 Analogues for Stress‐Related Eating and Role of GLP‐1 in Stress, Emotion and Mood: A Review,” Progress in Neuro‐Psychopharmacology and Biological Psychiatry 110 (August 2021): 110303, https://doi.org/10.1016/j.pnpbp.2021.110303.
E. M. Bomberg, J. Clark, K. D. Rudser, A. C. Gross, A. S. Kelly, and C. K. Fox, “Effectiveness and Predictors of Weight Loss Response to Phentermine Plus Lifestyle Modifications Among Youth in a Paediatric Weight Management Clinical Setting,” Pediatric Obesity 19 (June 2024): e13143, https://doi.org/10.1111/ijpo.13143.
A. Acosta, M. Camilleri, B. Abu Dayyeh, et al., “Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic,” Obesity 29, no. 4 (April 2021): 662–671, https://doi.org/10.1002/oby.23120.
F. Dehghani, M. Ali Ahmadi, M. Hefner, et al., “An Algorithm for the Use of Anti‐Obesity Medications,” Nutrition & Diabetes 14, no. 1 (April 2024): 20, https://doi.org/10.1038/s41387-024-00278-2.
Y. J. Ahn, J. Maya, and V. Singhal, “Update on Pediatric Anti‐Obesity Medications‐Current Landscape and Approach to Prescribing,” Current Obesity Reports 13, no. 2 (June 2024): 295–312, https://doi.org/10.1007/s13679-024-00566-z.